Get the Stockscreener App
8.72
1.28%
0.11
After Hours:
8.65
-0.07
-0.80%
Actuate Therapeutics Inc stock is traded at $8.72, with a volume of 86,042.
It is up +1.28% in the last 24 hours and up +23.34% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$8.61
Open:
$8.66
24h Volume:
86,042
Relative Volume:
0.87
Market Cap:
$180.90M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+6.08%
1M Performance:
+23.34%
6M Performance:
+24.22%
1Y Performance:
+6.41%
1-Day Range:
$8.55
$9.22
1-Week Range:
$8.02
$9.22
52-Week Range:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.72 | 180.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | B. Riley Securities | Buy |
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
What data driven models say about Actuate Therapeutics Inc.’s futureWeekly Investment Report & Entry Point Strategy Guides - Newser
Real time social sentiment graph for Actuate Therapeutics Inc.New Guidance & Verified Momentum Stock Watchlist - Newser
Will Actuate Therapeutics Inc. stock go up soonPrice Action & AI Driven Stock Movement Reports - Newser
Leading vs lagging indicators on Actuate Therapeutics Inc. performanceAnalyst Downgrade & Consistent Return Strategy Ideas - Newser
Can Actuate Therapeutics Inc. recover in the next quarterWeekly Earnings Recap & Stepwise Swing Trade Plans - Newser
Forecasting Actuate Therapeutics Inc. price range with options data2025 Retail Activity & Low Risk Entry Point Tips - Newser
Using economic indicators to assess Actuate Therapeutics Inc. potentialJuly 2025 Selloffs & Safe Entry Momentum Tips - Newser
How to read the order book for Actuate Therapeutics Inc.Gap Up & Consistent Profit Focused Trading Strategies - Newser
Regression analysis insights on Actuate Therapeutics Inc. performance2025 Historical Comparison & Reliable Intraday Trade Plans - Newser
Chart overlay techniques for tracking Actuate Therapeutics Inc.Weekly Trend Report & Low Risk High Reward Trade Ideas - Newser
Is Actuate Therapeutics Inc. impacted by rising ratesEarnings Performance Report & Trade Opportunity Analysis - khodrobank.com
Has Actuate Therapeutics Inc. formed a bullish divergence2025 Top Decliners & Proven Capital Preservation Methods - Newser
Exit strategy if you’re trapped in Actuate Therapeutics Inc.July 2025 Selloffs & Technical Confirmation Trade Alerts - Newser
Is Actuate Therapeutics Inc. still worth holding after the dipSell Signal & Daily Growth Stock Investment Tips - Newser
Predicting Actuate Therapeutics Inc. trend using moving averagesJuly 2025 Selloffs & Verified Momentum Stock Ideas - Newser
Actuate Therapeutics files $250M mixed securities shelf - MSN
How to track smart money flows in Actuate Therapeutics Inc.Weekly Loss Report & Accurate Technical Buy Alerts - Newser
Combining price and volume data for Actuate Therapeutics Inc.Earnings Miss & Daily Technical Stock Forecast Reports - Newser
Combining machine learning predictions for Actuate Therapeutics Inc.2025 Key Highlights & Capital Protection Trading Alerts - Newser
What technical models suggest about Actuate Therapeutics Inc.’s comebackJuly 2025 Action & Long-Term Growth Stock Strategies - Newser
When is the best time to exit Actuate Therapeutics Inc.Earnings Summary Report & Weekly Top Gainers Alerts - Newser
Should I set a stop loss on Actuate Therapeutics Inc.Trade Entry Report & Technical Entry and Exit Alerts - khodrobank.com
Can a trend reversal in Actuate Therapeutics Inc. lead to recoveryStock Surge & Risk Managed Investment Strategies - Newser
Can Actuate Therapeutics Inc. lead its sector in growthOil Prices & Safe Capital Growth Stock Tips - خودرو بانک
Is Actuate Therapeutics Inc. forming a bottoming baseWeekly Risk Summary & Weekly Market Pulse Alerts - Newser
Actuate Therapeutics Inc. Facing Inflection Point in Trend Analysis getLinesFromResByArray error: size == 0 - kangso.co.kr
Published on: 2025-09-01 18:50:37 - khodrobank.com
Published on: 2025-08-31 16:14:11 - Newser
Will Actuate Therapeutics Inc. stock split in the near futureTrend Reversal & Reliable Entry Point Alerts - Newser
Is a relief rally coming for Actuate Therapeutics Inc. holders2025 Market Outlook & Smart Swing Trading Alerts - Newser
Has Actuate Therapeutics Inc. found a price floorJuly 2025 Price Swings & Capital Efficient Trade Techniques - Newser
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Actuate Therapeutics Inc Stock (ACTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
| Fletcher Aaron G.L. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):